262 related articles for article (PubMed ID: 26336887)
21. Clinical validation of coexisting driver mutations in colorectal cancers.
Zheng G; Tseng LH; Haley L; Ibrahim J; Bynum J; Xian R; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2019 Apr; 86():12-20. PubMed ID: 30481508
[TBL] [Abstract][Full Text] [Related]
22. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
23. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
24. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
25. Mesonephric-like adenocarcinoma of the female genital tract: possible role of KRAS-targeted treatment-detailed molecular analysis of a case series and review of the literature for targetable somatic KRAS-mutations.
Brambs CE; Horn LC; Hiller R; Krücken I; Braun C; Christmann C; Monecke A; Höhn AK
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15727-15736. PubMed ID: 37668797
[TBL] [Abstract][Full Text] [Related]
26. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
[TBL] [Abstract][Full Text] [Related]
27. Mesonephric-like Endometrial Carcinoma: Results From Immunohistochemical Screening of 300 Endometrial Carcinomas and Carcinosarcomas for This Often Overlooked and Potentially Aggressive Entity.
Mills AM; Jenkins TM; Howitt BE; Fan J; Ring KL; Cook I
Am J Surg Pathol; 2022 Jul; 46(7):921-932. PubMed ID: 35195579
[TBL] [Abstract][Full Text] [Related]
28. Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer.
Zheng R; Shen Q; Mardekian S; Solomides C; Wang ZX; Evans NR
J Thorac Cardiovasc Surg; 2020 Aug; 160(2):e71-e79. PubMed ID: 32007245
[TBL] [Abstract][Full Text] [Related]
29. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
30. Comparative genomics of high grade neuroendocrine carcinoma of the cervix.
Hillman RT; Cardnell R; Fujimoto J; Lee WC; Zhang J; Byers LA; Ramalingam P; Leitao M; Swisher E; Futreal PA; Frumovitz M
PLoS One; 2020; 15(6):e0234505. PubMed ID: 32544169
[TBL] [Abstract][Full Text] [Related]
31. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients.
Hamzehzadeh L; Khadangi F; Ghayoor Karimiani E; Pasdar A; Kerachian MA
Curr Probl Cancer; 2018 Nov; 42(6):572-581. PubMed ID: 29921458
[TBL] [Abstract][Full Text] [Related]
32. CD10 expression in epithelial tissues and tumors of the gynecologic tract: a useful marker in the diagnosis of mesonephric, trophoblastic, and clear cell tumors.
Ordi J; Romagosa C; Tavassoli FA; Nogales F; Palacin A; Condom E; Torné A; Cardesa A
Am J Surg Pathol; 2003 Feb; 27(2):178-86. PubMed ID: 12548163
[TBL] [Abstract][Full Text] [Related]
33. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.
Zhang J; Zheng J; Yang Y; Lu J; Gao J; Lu T; Sun J; Jiang H; Zhu Y; Zheng Y; Liang Z; Liu T
Sci Rep; 2015 Dec; 5():18678. PubMed ID: 26691448
[TBL] [Abstract][Full Text] [Related]
34. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
35. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
[TBL] [Abstract][Full Text] [Related]
36. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
[TBL] [Abstract][Full Text] [Related]
37. [Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients].
Liu XN; Tian Z; Wei XF; Wang Q; Zhang JX; Jin MS; Duan XM
Zhonghua Bing Li Xue Za Zhi; 2019 May; 48(5):373-377. PubMed ID: 31104677
[No Abstract] [Full Text] [Related]
38. Mesonephric Adenocarcinoma of the Uterine Corpus: A Report on 2 Cases With Comparison to Its Cervical Counterpart.
Liang Y; Shi H; Zhu X; Yu M; Zhang X
Int J Gynecol Pathol; 2020 Nov; 39(6):546-551. PubMed ID: 31985582
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies.
Castiglione R; Alidousty C; Holz B; Wagener S; Baar T; Heydt C; Binot E; Zupp S; Kron A; Wolf J; Merkelbach-Bruse S; Reinhardt HC; Buettner R; Schultheis AM
Mod Pathol; 2019 May; 32(5):627-638. PubMed ID: 30459450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
